Skip to main content
OpenTrials
Completed

NCT Number: NCT01688531

A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients

Exploratory, international, multi-centre, randomized, investigator blinded study in acne

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Galderma Investigational site, Windsor, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects aged 18 to 35 years inclusive
  • Subjects with active, moderate acne

Exclusion criteria

  • The subject has a secondary acne form (chloracne, drug-induced acne, etc.) (Screening)
  • The subject has a severity of acne that is not amenable to treatment with CD0271-CD1579 (Screening)

Treatment and study plan

CD0271 0.1%/CD1579 2.5% gel

Drug

one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months

CD0271 0.1%/CD1579 2.5% gel vehicle

Drug

one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months

Primary outcomes

  1. Description and documentation of acne lesions

    Time frame: over 6 months

Secondary outcomes

  1. Treatment effect on acne lesions

    Time frame: over 6 months

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 20, 2012
Registry last updated
Sep 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.